SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Takeda Pharmaceutical Company Limited (TKPHF) trades at a trailing P/E of 0.5, forward P/E of 0.3. Trailing earnings yield is 196.08%, forward earnings yield 322.58%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.5); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); earnings yield beats bond yields (196.08%).
- Forward P/E 0.3 (down from trailing 0.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 196.08% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 322.58% as earnings recover.
Overall SharesGrow Score: 67/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TKPHF
Valuation Multiples
P/E (TTM)0.5
Forward P/E0.3
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.00
P/S Ratio0.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$67.23
Forward EPS (Est.)$112.17
Book Value / Share$0.00
Revenue / Share$2,853.97
FCF / Share$0.00
Yields & Fair Value
Earnings Yield196.08%
Forward Earnings Yield322.58%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$101.71 |
$1.81T |
$80.17B |
4.4% |
| 2017 |
$146.25 |
$1.73T |
$114.94B |
6.6% |
| 2018 |
$237.55 |
$1.77T |
$186.89B |
10.6% |
| 2019 |
$112.86 |
$2.1T |
$109.13B |
5.2% |
| 2020 |
$28.25 |
$3.29T |
$44.24B |
1.3% |
| 2021 |
$238.96 |
$3.2T |
$376.01B |
11.8% |
| 2022 |
$145.87 |
$3.57T |
$230.06B |
6.4% |
| 2023 |
$201.94 |
$4.03T |
$317.02B |
7.9% |
| 2024 |
$91.16 |
$4.26T |
$144.07B |
3.4% |
| 2024 |
$67.23 |
$4.58T |
$107.93B |
2.4% |
